Droxidopa NEW
| Price | $32 | $73 | $98 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-14 |
Product Details
| Product Name: Droxidopa | CAS No.: 23651-95-8 |
| Purity: 98.12% | Supply Ability: 10g |
| Release date: 2025/07/14 |
Product Introduction
Bioactivity
| Name | Droxidopa |
| Description | Droxidopa (L-DOPS) is an orally available prodrug of norepinephrine that is used in the treatment of symptomatic orthostatic hypotension due to neurogenic causes of autonomic failure. |
| In vivo | Droxidopa is administered orally and is absorbed and converted to norepinephrine by the enzyme dopa decarboxylase, which, together with endogenous norepinephrine, increases neurotransmitter levels.Droxidopa also crosses the blood-brain barrier (BBB) and is converted to norepinephrine and epinephrine in the brain. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.13 mg/ml (10 mM), Sonication is recommended. H2O : 1.25 mM, Sonication is recommended. |
| Keywords | SM-5688 | SM 5688 | orally active | neurogenic orthostatic hypotension | Inhibitor | inhibit | Droxidopa | blood pressure | Beta Receptor | AdrenergicReceptor | Adrenergic Receptor | ADHD |
| Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Tolazoline hydrochloride | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Atenolol |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-03-31 | |
| $19.00/1KG |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $8.00/1kg |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-23 | |
| $100.00/25kg |
VIP6Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2022-06-28 | |
| $0.00/1Kg |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY